sellWeak cluster of 210b5-1 plan
Fust Matthew K sold $371k of NMRA
director at Neumora Therapeutics, Inc.. 21,788 shares at an average of $17.03, traded Oct 17, 2024, filed Oct 18, 2024.
Warning score
23Value
$371k
21,788 shares
Holdings after
20,100
-78% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001610717-24-000511, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 17, 2024 | MOption exercise Common Stock10b5-1 | +3,783 | $8.32 | $31k | 23,883 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Common Stock10b5-1 | +1,800 | $8.79 | $16k | 25,683 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Common Stock10b5-1 | +2,156 | $2.52 | $5,433 | 27,839 | Oct 18, 2024 |
| Oct 17, 2024 | SOpen-market sale Common Stock10b5-1 | -7,739 | $17.01 | $132k | 20,100 | Oct 18, 2024 |
| Oct 18, 2024 | MOption exercise Common Stock10b5-1 | +6,205 | $8.79 | $55k | 26,305 | Oct 18, 2024 |
| Oct 18, 2024 | MOption exercise Common Stock10b5-1 | +7,844 | $2.52 | $20k | 34,149 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stock10b5-1 | -14,049 | $17.03 | $239k | 20,100 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,783 | $0.00 | $0 | 0 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,800 | $0.00 | $0 | 6,205 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,156 | $0.00 | $0 | 93,430 | Oct 18, 2024 |
| Oct 18, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,205 | $0.00 | $0 | 0 | Oct 18, 2024 |
| Oct 18, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,844 | $0.00 | $0 | 85,586 | Oct 18, 2024 |
Related signals
Other insiders at Neumora Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 3Weak | sell 210b5-1 | NMRA Neumora Therapeutics, Inc. | Aurora Daljit Singh Chief Strategy Officer | $14k | 8,565 | |
| 3Weak | sell 210b5-1 | NMRA Neumora Therapeutics, Inc. | BERNS PAUL L See Remarks | $23k | 13,871 | |
| 15Weak | sell 210b5-1 | NMRA Neumora Therapeutics, Inc. | Lenz Robert A. Head of R&D | $208k | 13,823 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.